Switch theme
Sign up to access all valuation multiples
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company’s products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
1932
2.8K+
LTM Revenue $585M
LTM EBITDA $88.5M
$402M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Boiron has a last 12-month revenue (LTM) of $585M and a last 12-month EBITDA of $88.5M.
In the most recent fiscal year, Boiron achieved revenue of $574M and an EBITDA of $68.5M.
Boiron expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Boiron valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $585M | XXX | $574M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $423M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $88.5M | XXX | $68.5M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 12% | XXX | XXX | XXX |
| EBIT | $32.7M | XXX | $42.2M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $23.5M | XXX | $13.4M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Boiron's stock price is EUR 22 (or $27).
Boiron has current market cap of EUR 391M (or $460M), and EV of EUR 341M (or $402M).
See Boiron trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $402M | $460M | XXX | XXX | XXX | XXX | $1.35 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Boiron has market cap of $460M and EV of $402M.
Boiron's trades at 0.7x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate Boiron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Boiron has a P/E ratio of 19.6x.
See valuation multiples for Boiron and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $460M | XXX | $460M | XXX | XXX | XXX |
| EV (current) | $402M | XXX | $402M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 4.5x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | 12.3x | XXX | 9.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.6x | XXX | 34.5x | XXX | XXX | XXX |
| EV/FCF | 5.3x | XXX | 14.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBoiron's last 12 month revenue growth is 3%
Boiron's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Boiron's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Boiron's rule of X is 24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Boiron and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Boiron acquired XXX companies to date.
Last acquisition by Boiron was XXXXXXXX, XXXXX XXXXX XXXXXX . Boiron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Boiron founded? | Boiron was founded in 1932. |
| Where is Boiron headquartered? | Boiron is headquartered in France. |
| How many employees does Boiron have? | As of today, Boiron has 2.8K+ employees. |
| Is Boiron publicy listed? | Yes, Boiron is a public company listed on PAR. |
| What is the stock symbol of Boiron? | Boiron trades under BOI ticker. |
| When did Boiron go public? | Boiron went public in 1989. |
| Who are competitors of Boiron? | Similar companies to Boiron include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Boiron? | Boiron's current market cap is $460M |
| What is the current revenue of Boiron? | Boiron's last 12 months revenue is $585M. |
| What is the current revenue growth of Boiron? | Boiron revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Boiron? | Current revenue multiple of Boiron is 0.7x. |
| Is Boiron profitable? | Yes, Boiron is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Boiron? | Boiron's last 12 months EBITDA is $88.5M. |
| What is Boiron's EBITDA margin? | Boiron's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Boiron? | Current EBITDA multiple of Boiron is 4.5x. |
| What is the current FCF of Boiron? | Boiron's last 12 months FCF is $75.3M. |
| What is Boiron's FCF margin? | Boiron's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Boiron? | Current FCF multiple of Boiron is 5.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
